Development of a method to implement whole-genome bisulfite sequencing of cfDNA from cancer patients and a mouse tumor model
EC Maggi, S Gravina, H Cheng, B Piperdi… - Frontiers in …, 2018 - frontiersin.org
Frontiers in genetics, 2018•frontiersin.org
The goal of this study was to develop a method for whole genome cell-free DNA (cfDNA)
methylation analysis in humans and mice with the ultimate goal to facilitate the identification
of tumor derived DNA methylation changes in the blood. Plasma or serum from patients with
pancreatic neuroendocrine tumors or lung cancer, and plasma from a murine model of
pancreatic adenocarcinoma was used to develop a protocol for cfDNA isolation, library
preparation and whole-genome bisulfite sequencing of ultra low quantities of cfDNA …
methylation analysis in humans and mice with the ultimate goal to facilitate the identification
of tumor derived DNA methylation changes in the blood. Plasma or serum from patients with
pancreatic neuroendocrine tumors or lung cancer, and plasma from a murine model of
pancreatic adenocarcinoma was used to develop a protocol for cfDNA isolation, library
preparation and whole-genome bisulfite sequencing of ultra low quantities of cfDNA …
The goal of this study was to develop a method for whole genome cell-free DNA (cfDNA) methylation analysis in humans and mice with the ultimate goal to facilitate the identification of tumor derived DNA methylation changes in the blood. Plasma or serum from patients with pancreatic neuroendocrine tumors or lung cancer, and plasma from a murine model of pancreatic adenocarcinoma was used to develop a protocol for cfDNA isolation, library preparation and whole-genome bisulfite sequencing of ultra low quantities of cfDNA, including tumor-specific DNA. The protocol developed produced high quality libraries consistently generating a conversion rate >98% that will be applicable for the analysis of human and mouse plasma or serum to detect tumor-derived changes in DNA methylation.
Frontiers